Navigation Links
Hospira Announces Certain Preliminary Third-Quarter 2011 Results
Date:10/18/2011

LAKE FOREST, Ill., Oct. 18, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that its preliminary third-quarter 2011 net sales, adjusted* income from operations and adjusted* earnings per share are lower than anticipated primarily due to certain quality actions taken in response to a U.S. Food and Drug Administration (FDA) 2010 warning letter and subsequent observations related to the company's manufacturing facility in Rocky Mount, North Carolina, and device quality and supply-related issues.

"While recently launched product sales continue to drive top-line growth, we were extremely disappointed in the third quarter by developments related to our quality-improvement initiatives that resulted in a significant slowdown of production and an associated impact on our operating performance," said F. Michael Ball, chief executive officer. "As I indicated at our Investor Day in early September, addressing these issues is Hospira's top priority, and our organization is committed to full resolution. I remain confident that Hospira will emerge from this process a stronger, more competitive global company that is optimally positioned to serve the needs of our customers and patients, and deliver strong value to our shareholders."

Preliminary net sales for the quarter were $977 million, an increase of 2.9 percent compared to $949 million in the third quarter of 2010, with the increase primarily driven by continued strong U.S. net sales of the oncolytic docetaxel. On a constant-currency basis, third-quarter net sales increased slightly compared to the third quarter of 2010.

Preliminary adjusted* income from operations for the third quarter of 2011 was $142 million compared to $189 million in the third quarter of 2010. The decline is primarily due to
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Hospira to Host Conference Call for Third-Quarter 2011 Results
2. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
3. Hospira to Host 2011 Investor Day
4. Hospira to Present at the Morgan Stanley Global Healthcare Conference
5. Hospira Expands Board of Directors
6. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
7. Hospira Reports Second-Quarter 2011 Results
8. Hospira to Host Conference Call for Second-Quarter 2011 Results
9. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
10. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
11. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... U.S. Food and Drug Administration has scheduled its fourth ... those unfamiliar with the process for Feb. 28 – ... Keck Graduate Institute. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... Organization of Rare Disorders and the Genetic Alliance, will ...
... /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical ... today announced that Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), ... a "Top Ten Branded Company Trusted by Consumers" ...
Cached Medicine Technology:Fourth FDA Orphan Drug Designation Workshop Scheduled for Feb. 28 - March 1, 2011 2China Sky One Medical Receives Medical Industry Awards 2China Sky One Medical Receives Medical Industry Awards 3
(Date:1/22/2015)... 2015 Deer Path of Huntley -- ... Day Happy Hour from 3 p.m. to 4 p.m. on Feb. ... in Huntley, Illinois, serves adults with physical disabilities between the ages ... Valentine's Day treats, games and sweetheart-themed karaoke. , For more information ...
(Date:1/22/2015)... Liberty University has received accreditation for its resident ... Council for Accreditation of Counseling & Related Educational Programs ... Counseling & Family Studies , is under the leadership of ... of Behavioral Sciences. Prior to the formation of the new ...
(Date:1/22/2015)... 22, 2015 The City of West Hollywood hosted ... to commemorate the 42nd anniversary of the Supreme Court decision Roe ... been 42 years since the Roe vs. Wade decision and the ... present as ever,” said City of West Hollywood Councilmember Abbe Land. ...
(Date:1/22/2015)... TN (PRWEB) January 22, 2015 Gabe’s Chemo Duck ... Duck App, the first app ever created for kids with cancer. ... Apple phones and devices, is filled with enjoyable games to help ... and treatments. The free app helps to keep kids entertained, educated ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... A study by researchers at UC Davis has found that ... to produce autoantibodies to the brains of their developing fetuses ... risk of later being diagnosed with autism. The finding ... in the development of the neurodevelopmental disorder among some children ...
... Canadian Journal of Cardiology ( www.onlinecjc.ca ) ... imaging methods. This study is important for patients worried ... heart. X-ray based methods have greatly improved the diagnosis ... of radiation exposure. New imaging methods offer ...
... Serena Gordon HealthDay Reporter , TUESDAY, Oct. ... the way that parts of kidney dialysis machines are ... A recently developed sterilization method called electron ... platelets in the blood of dialysis patients, according to ...
... online Oct. 18 in the Journal of the National ... the idea that the immune system,s response to allergies may ... with somewhat elevated blood levels of immunoglobulin E (IgE), antibodies ... significantly less likely to develop gliomas, and those who did ...
... Ind. -- A new study by researchers at Indiana University ... men surprisingly diverse, suggesting that a broader, less disease-focused perspective ... addressing the sexual health of gay and bisexual men. ... Journal of Sexual Medicine, tapped the largest sample ...
... population will nearly double by 2050, according to a ... exists as to who will care for them as ... but those caregiving roles are becoming blurred as more ... previous decades. Now, University of Missouri researchers have found ...
Cached Medicine News:Health News:Genetic variant and autoantibodies linked to having a child with autism 2Health News:Genetic variant and autoantibodies linked to having a child with autism 3Health News:Genetic variant and autoantibodies linked to having a child with autism 4Health News:Study Links New Dialysis Technology to Rise in Bleeding Risk 2Health News:Study Links New Dialysis Technology to Rise in Bleeding Risk 3Health News:More evidence that allergies may help in fighting brain tumors 2Health News:New study finds gay and bisexual men have varied sexual repertoires 2Health News:New study finds gay and bisexual men have varied sexual repertoires 3Health News:Relationships more important than genetic ties when deciding who cares for aging family, study finds 2
Unipolar Atrial "J" Lead...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: